Sesen Bio Stock Forecast, Price & News

-0.18 (-4.14 %)
(As of 06/21/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume6.56 million shs
Average Volume6.52 million shs
Market Capitalization$722.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SESN News and Ratings via Email

Sign-up to receive the latest news and ratings for Sesen Bio and its competitors with MarketBeat's FREE daily newsletter.

Sesen Bio logo

About Sesen Bio

Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment patients with cancer. The company's lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of BCG-unresponsive non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a product candidate for use in the treatment of various types of an anti-epithelial cell adhesion molecule (EpCAM)-positive solid tumors. It also develops Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of BCG-unresponsive NMIBC; and Vicinium in combination with AstraZeneca's checkpoint inhibitor for the treatment of squamous cell carcinoma of the head and neck. Sesen Bio, Inc. has an agreement with Leiden University Medical Center to co-develop an imaging agent. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.35 out of 5 stars

Medical Sector

814th out of 2,101 stocks

Pharmaceutical Preparations Industry

399th out of 831 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Sesen Bio (NASDAQ:SESN) Frequently Asked Questions

Is Sesen Bio a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sesen Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sesen Bio stock.
View analyst ratings for Sesen Bio
or view top-rated stocks.

What stocks does MarketBeat like better than Sesen Bio?

Wall Street analysts have given Sesen Bio a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sesen Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Sesen Bio?

Sesen Bio saw a increase in short interest in May. As of May 14th, there was short interest totaling 7,920,000 shares, an increase of 64.3% from the April 29th total of 4,820,000 shares. Based on an average trading volume of 5,270,000 shares, the short-interest ratio is currently 1.5 days.
View Sesen Bio's Short Interest

When is Sesen Bio's next earnings date?

Sesen Bio is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Sesen Bio

How were Sesen Bio's earnings last quarter?

Sesen Bio, Inc. (NASDAQ:SESN) issued its quarterly earnings results on Sunday, May, 9th. The company reported ($0.35) EPS for the quarter, missing the Zacks' consensus estimate of ($0.08) by $0.27.
View Sesen Bio's earnings history

How has Sesen Bio's stock been impacted by COVID-19?

Sesen Bio's stock was trading at $0.72 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SESN stock has increased by 479.2% and is now trading at $4.17.
View which stocks have been most impacted by COVID-19

What price target have analysts set for SESN?

2 brokers have issued 12 month price objectives for Sesen Bio's stock. Their forecasts range from $7.00 to $8.00. On average, they anticipate Sesen Bio's share price to reach $7.50 in the next twelve months. This suggests a possible upside of 79.9% from the stock's current price.
View analysts' price targets for Sesen Bio
or view top-rated stocks among Wall Street analysts.

Who are Sesen Bio's key executives?

Sesen Bio's management team includes the following people:
  • Dr. Thomas R. Cannell, Pres, CEO & Director (Age 59, Pay $885.06k)
  • Ms. Monica Forbes, CFO & Treasurer (Age 45, Pay $536k)
  • Dr. Glen C. MacDonald, Chief Technology Officer (Age 70, Pay $519.7k)
  • Dr. Gregory L. Verdine, Co-Founder (Age 62)
  • Ms. Elly Ryu, Corp. Controller & Principal Accounting Officer (Age 40)
  • Ms. Erin Clark, VP of Corp. Strategy & Investor Relations
  • Mr. Mark R. Sullivan, Gen. Counsel & Corp. Sec. (Age 50)
  • Dr. David Brooks, Sr. VP of Clinical Devel.
  • Dr. Dennis Kim M.D., MPH, Chief Medical Officer (Age 52)
  • Ms. Kirstin Nettelbladt Anderson, Sr. Director of Fin. (Age 47)

Who are some of Sesen Bio's key competitors?

What other stocks do shareholders of Sesen Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sesen Bio investors own include Amarin (AMRN), XOMA (XOMA), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Verastem (VSTM), Sorrento Therapeutics (SRNE), Novavax (NVAX), Biocept (BIOC), Micron Technology (MU) and OPKO Health (OPK).

What is Sesen Bio's stock symbol?

Sesen Bio trades on the NASDAQ under the ticker symbol "SESN."

Who are Sesen Bio's major shareholders?

Sesen Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include TRV GP LLC (2.42%), Renaissance Technologies LLC (2.16%), Schonfeld Strategic Advisors LLC (1.94%), BlackRock Inc. (1.73%), Millennium Management LLC (0.94%) and Geode Capital Management LLC (0.77%).

Which major investors are selling Sesen Bio stock?

SESN stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Bank of New York Mellon Corp, and Private Advisor Group LLC.

Which major investors are buying Sesen Bio stock?

SESN stock was purchased by a variety of institutional investors in the last quarter, including TRV GP LLC, Schonfeld Strategic Advisors LLC, BlackRock Inc., Millennium Management LLC, Renaissance Technologies LLC, Cubist Systematic Strategies LLC, Geode Capital Management LLC, and HRT Financial LP.

How do I buy shares of Sesen Bio?

Shares of SESN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sesen Bio's stock price today?

One share of SESN stock can currently be purchased for approximately $4.17.

How much money does Sesen Bio make?

Sesen Bio has a market capitalization of $722.61 million and generates $11.24 million in revenue each year. The company earns $-22,400,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis.

How many employees does Sesen Bio have?

Sesen Bio employs 27 workers across the globe.

What is Sesen Bio's official website?

The official website for Sesen Bio is

Where are Sesen Bio's headquarters?

Sesen Bio is headquartered at 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142.

How can I contact Sesen Bio?

Sesen Bio's mailing address is 245 FIRST STREET SUITE 1800, CAMBRIDGE MA, 02142. The company can be reached via phone at 617-444-8550 or via email at [email protected]

This page was last updated on 6/21/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.